XOMA Royalty Announces Cash Dividends for Preferred Stock Holders
XOMA Royalty Corporation's Commitment to Investors
XOMA Royalty Corporation has always prioritized its investors, and the recent decision by its Board of Directors demonstrates that commitment. The company has officially announced cash dividends for holders of its preferred stock, specifically for the Series A and Series B Cumulative Preferred Stocks.
Details of the Preferred Stock Dividends
For those holding the 8.625% Series A Cumulative Perpetual Preferred Stock, a cash dividend of $0.53906 per share will be distributed. Meanwhile, holders of the 8.375% Series B Cumulative Perpetual Preferred Stock will receive a cash dividend of $0.52344 per depositary share. These dividends showcase the company's strong commitment to its shareholders and reflect its robust financial health.
Important Dates for Stockholders
These announced dividends are expected to be issued on or around October 15, with the record date set for October 3. Shareholders should ensure their ownership records are in order to receive these dividends promptly. This initiative offers financial rewards to investors, reinforcing XOMA's dedication to maintaining and enhancing shareholder value.
Understanding XOMA Royalty’s Business Model
XOMA Royalty stands out in the biotechnology field as a leading royalty aggregator. Its strategic acquisitions involve obtaining future economic rights associated with promising pre-commercial therapeutic candidates and existing commercial assets licensed to various biotech or pharmaceutical companies. This unique position allows the company to provide non-dilutive funding to sellers, aiding in the development of new and innovative drugs while strengthening its asset portfolio.
Diverse Portfolio of Assets
As of now, XOMA has an impressive portfolio comprising over 70 unique assets. Each asset represents the right to receive potential future economics tied to the advancement of therapeutics. The company’s approach not only benefits the funds required for drug development but also enriches its own strategic holdings.
Commercial Assets Overview
Within XOMA Royalty’s extensive portfolio, several commercial assets are currently recognized, including VABYSMO (faricimab-svoa) and IXINITY (coagulation factor IX). Each of these products reflects the potential for success in the market, thus solidifying XOMA's position within the industry as a forward-thinking entity.
Investor Relations and Contact Information
XOMA Royalty values transparency and accessibility with its investors. For inquiries, shareholders can reach out to Juliane Snowden, the Investor Contact, at +1 646-438-9754 or via email. This open line of communication emphasizes the company’s commitment to its shareholders.
Frequently Asked Questions
What are the announced cash dividends from XOMA Royalty?
The cash dividends include $0.53906 per share for Series A holders and $0.52344 per depositary share for Series B holders.
When will the dividends be paid out?
The dividends are expected to be paid on or about October 15, 2024, with a record date of October 3, 2024.
What is the primary focus of XOMA Royalty?
XOMA Royalty specializes in acquiring royalty rights from biotechnology firms, providing them with funding while securing economic rights for future therapeutic advancements.
How many assets does XOMA Royalty currently have?
XOMA Royalty boasts a portfolio of more than 70 assets, allowing it to maintain a diverse and promising collection of economic rights.
Who can investors contact for inquiries?
Investors can contact Juliane Snowden at XOMA Royalty Corporation through the provided phone number or email for any questions or concerns.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- David Tepper's Optimism for Chinese Stocks Amid Stimulus Push
- Investors Urged to Act Before Deadline on Orthofix Case
- Bristol Myers Squibb's Breakthrough Approval of COBENFY for Schizophrenia
- Investigation into Sun Communities Raises Questions for Investors
- Class Actions Announced for GitLab, Outset Medical, and Others
- Recent Class Action Suits Highlight Challenges for Investors
- Australia and China Strengthen Economic Collaboration Efforts
- Thermoform Packaging Growth Projections and Market Insights
- DexCom Investors Alert: Class Action Lawsuit Filed for Securities
- Cathie Wood's ARK ETF Expands Investment in Amazon Stock
Recent Articles
- Apple's Software Focus: A Shift from Hardware Innovation
- WuXi Biologics Celebrates Inclusion in Prestigious ESG Index
- How Tesla's Robotaxi Reveal Could Change Everything for Stock
- Lennar Corporation's Strategic Growth: A Balanced Outlook Ahead
- Citi's Positive Outlook: Dover Corp's Growth in CO2 Systems
- Regeneron's Growth Journey: Unpacking Future Potential and Challenges
- How Billionaire Hedge Fund Managers Are Diversifying to Bitcoin
- Unlocking Nvidia's $1 Trillion Opportunity Beyond AI Insights
- Zelenskyy’s Strategic Visit to the U.S. for Peace in Ukraine
- Exploring the Essence of the Silk Road Film Festival in Xi'an
- Surge in Flight Demand Linked to Taylor Swift's Eras Tour
- Transforming Investment: INX's New Tokenized Stocks on Polygon
- Teroxx Shines Bright at Global Brand Awards for Innovation
- Challenges Facing Hays Plc: Insights from BNP Paribas
- Citi Lowers So-Young Stock Rating Amid Market Challenges
- Commerzbank Shares Stabilize as German Government Retains Stake
- Gold Prices Rally as Investment Shifts Amid Global Uncertainty
- Costco's Potential Stock Split: What Investors Need to Know
- Intimate Lingerie Market Expected to Reach $23 Billion by 2032
- Explore OKX's New Listing of Catizen's CATI Token
- Northern 3 VCT PLC Plans Major Fundraising Effort Ahead
- Northern 2 VCT PLC Plans Fundraising with Northern VCTs
- Northern Venture Trust PLC Announces Fundraising Plans for Growth
- International Petroleum Corporation Shares Buyback Update
- International Petroleum Corporation Reports Share Buyback Success
- Realkredit Danmark A/S Announces Recent Prepayments Update
- Innovative Challenge for Smart Cities at SCEWC Unveiled
- Antengene's XPOVIO® Gains Approval in Thailand for Cancer Treatment
- XCMG Unveils New XDE260 Dump Truck for Mining Operations
- Highlights from the 2024 Gaobeidian International Windoor Festival
- UBS Backing Marks & Spencer: Growth Prospects Shine Bright
- Market Movements: Fed Insights and Investment Strategies Unveiled
- Morgan Stanley's Shift: Balancing Defensives and Cyclicals
- Qualcomm Explores Acquisition Talks with Intel Amid Challenges
- Sydbank's Share Buyback Initiative: Week 38 Report
- Adarga Enhances Military Intelligence with AI Software
- Leadership Enhancements at Broken String Biosciences Unveiled
- Top Stocks to Watch: AAR, ShiftPixy, and More Insights
- General Motors Plans Workforce Reduction Amid EV Transition
- Innovative Heart Disease Treatments Set for Global Conference
- Innovative Solutions from the International Low-Altitude Economy Conference
- Promoting Global Understanding: Insights from Beijing Forum
- Exciting Airdrop Campaign with Flipster and Hamster Kombat
- EU Challenges China's Dairy Subsidy Investigation at WTO
- Mercedes-Benz Faces Downgrade Amid Weaker China Demand
- Deutsche Bank Optimizes GEA Group Shares Target with New Strategy
- Zalando Stock Target Raised Amid Consumer Rebound Signals
- Kerry Group Receives Support from Analysts Amid Growth Prospects
- BMO Capital Optimistic About OneStream's Growth Prospects
- Rightmove's Share Prices Surge, Rejecting REA Group's Bid